Results 81 to 90 of about 59,797 (283)
BMEMat, EarlyView.This review comprehensively summarizes emerging biomaterial‐based strategies and underlying mechanisms for modulating endogenous tendon stem/progenitor cells (TSPCs). It offers the most recent insights into TSPC physiology and potential applications of tissue engineering and regenerative medicine in tendons.
Zeyu Zhu +9 more
wiley +1 more source
Nature Communications, 2018 Dopamine receptor agonists are used for the treatment of various psychiatric diseases. Here, the authors screen approximately three million compounds and identify a novel class of D1R agonists that do not have a catechol scaffold and possess promising ...
David L. Gray +12 more
doaj +1 more source
On the importance of including both sexes in animal studies – insights from home‐cage monitoring
Biological Reviews, EarlyView.ABSTRACT A review of behavioural studies using home‐cage monitoring (HCM) systems revealed that over 61% of studies used only male subjects, with only 24% including both sexes, despite evidence of substantial behavioural differences between male and female animals. This bias could influence the outcomes of biomedical research.
Maša Čater +12 more
wiley +1 more source
, 2012 The mesoaccumbens dopamine system has been implicated in many basic psychological processes (e.g. "wanting" and "liking") and illnesses (e.g. addiction, depression, schizophrenia).
Wilson, David Ian Greig
core
Dopamine agonists delayed or missed dosages (n = 213).
, 2015 Dopamine agonists delayed or missed dosages (n = 213).
John P. Chapman (725861) +8 more
core +1 more source
A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders
Clinical Pharmacology &Therapeutics, EarlyView.Parkinsonian disorders, including Parkinson's disease, Lewy body dementia, multiple system atrophy, and progressive supranuclear palsy, are progressive neurodegenerative conditions with no treatment options to slow disease progression. This systematic review provides an overview of evidence of disease‐modifying therapies that have been evaluated in ...
Pepijn P.N.M. Eijsvogel +3 more
wiley +1 more source
Prescribing pattern of anti-Parkinson drugs in Japan: a trend analysis from 2005 to 2010.
PLoS ONE, 2014 ObjectiveTherapeutic options for Parkinson's disease mainly consist of L-dopa and dopamine agonists. However, in Japan, the product labeling of the ergot dopamine agonists, cabergoline and pergolide, was revised in April 2007 due to the risk of ...
Sachiko Nakaoka +6 more
doaj +1 more source
The Role of Opioids on Motor Activity in Physio-pathological Conditions
, 2009 To date, four principal classes of opioid peptide receptors, μ (MOP), κ (KOP), δ (DOP) and ORL- 1 (NOP) have been identified and cloned. The experimental and clinical importance of this receptor family has been amply demonstrated in many diseases ...
Mabrouk, Omar Sharif
core
Clinical Pharmacology &Therapeutics, EarlyView.Major depressive disorder (MDD) and treatment‐resistant depression (TRD) remain leading causes of disability, providing the impetus for receptor‐level treatment strategies beyond monoamine reuptake. The serotonin 5‐HT2B receptor (5‐HT2BR) is uniquely positioned at the interface of central‐antidepressant mechanisms and peripheral cardiac risks.
Gia Han Le +8 more
wiley +1 more source
Pramipexole use and the risk of pneumonia
BMC Neurology, 2012 Background Patients with Parkinson's disease have an elevated risk of pneumonia and randomized trials suggest that this risk may be increased with the dopamine agonist pramipexole.
Ernst Pierre +3 more
doaj +1 more source